Summit Therapeu ADR (SMMT)

$21.35 -1.30 (-5.74%)
Market Cap 16.83B
Revenue (ttm) 0.00
Net Income (ttm) -221.32M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 2,652,600
Avg Vol 4,052,364
Day's Range N/A - N/A
Shares Out 742.85M
Stochastic %K 32%
Beta -1.13
Analysts Strong Sell
Price Target $32.69

Company Profile

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small lung cancer. The company was founded in 2003 and is headquartered in Miami, Florida.

Industry: Biotechnology
Sector: Healthcare
Phone: 305 203 2034
Address:
601 Brickell Key Drive, Suite 1000, Miami, United States
RadioIsotope25
RadioIsotope25 Oct. 11 at 1:24 PM
$SMMT $CHRS $NVS Fusion, RayzeBio, Point Bio all Billion dollar buyouts in radiopharma. Who’s next $RADX ???
0 · Reply
RadioIsotope25
RadioIsotope25 Oct. 10 at 11:39 PM
$RADX Could be sitting on the next $SMMT
0 · Reply
Halbalidiya
Halbalidiya Oct. 10 at 6:50 PM
$SMMT dont worry, duggan will buy more to prop up his shell company and stoke the flames of hopium
1 · Reply
BOXLinvestor
BOXLinvestor Oct. 10 at 4:43 PM
$SMMT Summit Therapeutics (option volume 10-10-25) 21.70 –4.2% | 367 trades | total $323.2 K | 90-day avg $1.66 M × 0.19 call $280.1 K | put $43.1 K | 97% single-leg, 3% multi-leg
0 · Reply
TruthBroker2
TruthBroker2 Oct. 10 at 1:16 PM
$PLSE $SMMT
0 · Reply
_ThanosTrajectorys
_ThanosTrajectorys Oct. 10 at 11:20 AM
Keep a close watch on CMCT! This stock has a nano float of just 700k + DIVIDENDS $CTM $APA $SMMT $WIMI 6
0 · Reply
ChillPill1972
ChillPill1972 Oct. 9 at 10:40 PM
$SMMT We should get another PR prior to ESMO next weekend!
0 · Reply
Omegacy2
Omegacy2 Oct. 9 at 9:19 PM
$SMMT was 23.5 now 22 i called it 20-19. $NBIS was 135 now 132.4s hod 133.3s. i called it 86-87. i got it right again. in few weeks. @EnvyMyPortfolio
0 · Reply
Magic8BallResponse
Magic8BallResponse Oct. 9 at 7:34 PM
$SMMT
0 · Reply
ArbiterOfFarts
ArbiterOfFarts Oct. 9 at 7:30 PM
$IOVA I Don't follow IOVA, but when IOVA people come over to $SMMT to shit on it they always talk about how IOVA has a product that is out and it works well. I'm not here to say it doesn't work well because I've done zero research, my legitimate question is, if what you have works and works well why has this not broken out yet?
4 · Reply
Latest News on SMMT
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 24, 2025, 4:30 PM EDT - 16 days ago

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025

Sep 24, 2025, 7:00 AM EDT - 17 days ago

HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025

Ten Bull Market 10-Baggers

Sep 22, 2025, 2:45 PM EDT - 18 days ago

Ten Bull Market 10-Baggers

APP CVNA FTAI HOOD MSTR NVDA PLTR

Summit Therapeutics: Buy the Next Dip Amid Clinical Breakthrough Potential

Sep 17, 2025, 10:54 PM EDT - 23 days ago

Summit Therapeutics: Buy the Next Dip Amid Clinical Breakthrough Potential

Summit Therapeutics Inc. Investigated by the Portnoy Law Firm

Sep 16, 2025, 4:31 PM EDT - 24 days ago

Summit Therapeutics Inc. Investigated by the Portnoy Law Firm

CORRECTION -- Summit Therapeutics Inc. Investigated by the Portnoy Law Firm

Sep 10, 2025, 12:43 AM EDT - 4 weeks ago

CORRECTION -- Summit Therapeutics Inc. Investigated by the Portnoy Law Firm

Top 3 Health Care Stocks You'll Regret Missing In Q3

Sep 9, 2025, 9:12 AM EDT - 4 weeks ago

Top 3 Health Care Stocks You'll Regret Missing In Q3

CERO

Summit Therapeutics (SMMT) WCLC Update Call (Transcript)

Sep 8, 2025, 3:36 PM EDT - 4 weeks ago

Summit Therapeutics (SMMT) WCLC Update Call (Transcript)

Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences

Sep 8, 2025, 8:28 AM EDT - 4 weeks ago

Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences

New Fortress Energy Posts Q2 Loss, Joins Summit Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Sep 8, 2025, 8:10 AM EDT - 4 weeks ago

New Fortress Energy Posts Q2 Loss, Joins Summit Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session

NFE

Ivonescimab Plus Chemotherapy Demonstrates Consistent Global Benefit: HARMONi Data Update Shows OS HR=0.78, Nominal P=0.0332

Sep 7, 2025, 6:08 AM EDT - 4 weeks ago

Ivonescimab Plus Chemotherapy Demonstrates Consistent Global Benefit: HARMONi Data Update Shows OS HR=0.78, Nominal P=0.0332

Longer-Term Follow-Up of Western Patients Showed Improving, Favorable Trend in Overall Survival in Global Phase III HARMONi Clinical Trial for Ivonescimab Plus Chemotherapy in 2L+ EGFRm NSCLC

Sep 7, 2025, 3:30 AM EDT - 4 weeks ago

Longer-Term Follow-Up of Western Patients Showed Improving, Favorable Trend in Overall Survival in Global Phase III HARMONi Clinical Trial for Ivonescimab Plus Chemotherapy in 2L+ EGFRm NSCLC

Summit Therapeutics to Host Update Call at WCLC 2025 on September 8, 2025

Sep 3, 2025, 7:00 AM EDT - 5 weeks ago

Summit Therapeutics to Host Update Call at WCLC 2025 on September 8, 2025

Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says Analyst

Aug 27, 2025, 2:43 PM EDT - 6 weeks ago

Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says Analyst

Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025

Aug 14, 2025, 7:00 AM EDT - 2 months ago

Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025

Aug 11, 2025, 5:03 PM EDT - 2 months ago

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025

SMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law Firm

Jul 14, 2025, 3:00 PM EDT - 3 months ago

SMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law Firm

Summit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks Remain

Jul 4, 2025, 5:10 AM EDT - 3 months ago

Summit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks Remain

AZN

Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors

Jun 30, 2025, 8:00 AM EDT - 3 months ago

Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors

RVMD

Summit Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

Jun 5, 2025, 8:00 AM EDT - 4 months ago

Summit Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

Summit Therapeutics: Market Overreaction Creates Opportunity

Jun 2, 2025, 2:52 PM EDT - 4 months ago

Summit Therapeutics: Market Overreaction Creates Opportunity

Is SMMT Stock A Buy After Its Recent Plunge?

Jun 2, 2025, 9:10 AM EDT - 4 months ago

Is SMMT Stock A Buy After Its Recent Plunge?

Summit Therapeutics: Moving Stock To 'Hold' Rating After Phase 3 HARMONi Data Release

May 30, 2025, 2:50 PM EDT - 4 months ago

Summit Therapeutics: Moving Stock To 'Hold' Rating After Phase 3 HARMONi Data Release

Summit Therapeutics Study Is a Win for China Biopharma Deals. Why the Stock Is Down.

May 30, 2025, 9:27 AM EDT - 4 months ago

Summit Therapeutics Study Is a Win for China Biopharma Deals. Why the Stock Is Down.

Summit Therapeutics' Closely-Watched Lung Cancer Study Of Ivonescimab Misses Overall Survival Endpoint

May 30, 2025, 9:01 AM EDT - 4 months ago

Summit Therapeutics' Closely-Watched Lung Cancer Study Of Ivonescimab Misses Overall Survival Endpoint

Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer after EGFR TKI Therapy in Global Study

May 30, 2025, 6:00 AM EDT - 4 months ago

Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer after EGFR TKI Therapy in Global Study

Summit Therapeutics Inc. (SMMT) Q1 2025 Earnings Call Transcript

May 2, 2025, 1:06 AM EDT - 5 months ago

Summit Therapeutics Inc. (SMMT) Q1 2025 Earnings Call Transcript

Final Trade: NVS, XLU and SMMT

May 1, 2025, 6:20 PM EDT - 5 months ago

Final Trade: NVS, XLU and SMMT

NVS XLU

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025

May 1, 2025, 4:09 PM EDT - 5 months ago

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025

Why Is Summit Therapeutics Stock Trading Higher On Monday?

Apr 28, 2025, 1:00 PM EDT - 5 months ago

Why Is Summit Therapeutics Stock Trading Higher On Monday?

What's Going On With Summit Therapeutics Stock On Friday?

Apr 25, 2025, 3:14 PM EDT - 6 months ago

What's Going On With Summit Therapeutics Stock On Friday?

Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso in China

Apr 25, 2025, 2:50 PM EDT - 6 months ago

Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso in China

Summit Therapeutics to Host First Quarter 2025 Financial Results & Operational Progress Call on May 1, 2025

Apr 24, 2025, 4:15 PM EDT - 6 months ago

Summit Therapeutics to Host First Quarter 2025 Financial Results & Operational Progress Call on May 1, 2025

Why Is Summit Therapeutics Stock Soaring On Wednesday?

Apr 23, 2025, 3:47 PM EDT - 6 months ago

Why Is Summit Therapeutics Stock Soaring On Wednesday?

Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China

Apr 23, 2025, 6:15 AM EDT - 6 months ago

Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China

Summit Therapeutics: Multibillion Dollar NSCLC Potential Faces Growing Competition

Apr 14, 2025, 9:08 AM EDT - 6 months ago

Summit Therapeutics: Multibillion Dollar NSCLC Potential Faces Growing Competition

Analyst Initiates Coverage On 'Undervalued' Summit Therapeutics

Mar 24, 2025, 2:17 PM EDT - 7 months ago

Analyst Initiates Coverage On 'Undervalued' Summit Therapeutics

Robert LaCaze, Innovative Growth-Driver in Oncology, Joins Summit Therapeutics as Chief Commercial Officer

Mar 17, 2025, 4:24 PM EDT - 7 months ago

Robert LaCaze, Innovative Growth-Driver in Oncology, Joins Summit Therapeutics as Chief Commercial Officer

Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs

Feb 24, 2025, 8:13 PM EST - 8 months ago

Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs

PFE

Summit Therapeutics: Mid-2025 NSCLC Data Could Further Entrench Ivonescimab Program

Feb 24, 2025, 3:33 PM EST - 8 months ago

Summit Therapeutics: Mid-2025 NSCLC Data Could Further Entrench Ivonescimab Program

Summit Therapeutics Inc. (SMMT) Q4 2024 Earnings Call Transcript

Feb 24, 2025, 12:15 PM EST - 8 months ago

Summit Therapeutics Inc. (SMMT) Q4 2024 Earnings Call Transcript

Pfizer: What The Summit Therapeutics Deal Brings

Feb 24, 2025, 10:53 AM EST - 8 months ago

Pfizer: What The Summit Therapeutics Deal Brings

PFE

Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Twelve Months Ended December 31, 2024

Feb 24, 2025, 6:05 AM EST - 8 months ago

Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Twelve Months Ended December 31, 2024

Summit Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Ivonescimab in Combination with Pfizer Antibody Drug Conjugates (ADCs)

Feb 24, 2025, 6:00 AM EST - 8 months ago

Summit Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Ivonescimab in Combination with Pfizer Antibody Drug Conjugates (ADCs)

PFE

Summit Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results & Operational Progress Call on February 24, 2025

Feb 18, 2025, 9:00 AM EST - 8 months ago

Summit Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results & Operational Progress Call on February 24, 2025

Summit Therapeutics: Data Signals A Potential Paradigm Shift In NSCLC (Rating Upgrade)

Jan 18, 2025, 9:33 AM EST - 9 months ago

Summit Therapeutics: Data Signals A Potential Paradigm Shift In NSCLC (Rating Upgrade)

RadioIsotope25
RadioIsotope25 Oct. 11 at 1:24 PM
$SMMT $CHRS $NVS Fusion, RayzeBio, Point Bio all Billion dollar buyouts in radiopharma. Who’s next $RADX ???
0 · Reply
RadioIsotope25
RadioIsotope25 Oct. 10 at 11:39 PM
$RADX Could be sitting on the next $SMMT
0 · Reply
Halbalidiya
Halbalidiya Oct. 10 at 6:50 PM
$SMMT dont worry, duggan will buy more to prop up his shell company and stoke the flames of hopium
1 · Reply
BOXLinvestor
BOXLinvestor Oct. 10 at 4:43 PM
$SMMT Summit Therapeutics (option volume 10-10-25) 21.70 –4.2% | 367 trades | total $323.2 K | 90-day avg $1.66 M × 0.19 call $280.1 K | put $43.1 K | 97% single-leg, 3% multi-leg
0 · Reply
TruthBroker2
TruthBroker2 Oct. 10 at 1:16 PM
$PLSE $SMMT
0 · Reply
_ThanosTrajectorys
_ThanosTrajectorys Oct. 10 at 11:20 AM
Keep a close watch on CMCT! This stock has a nano float of just 700k + DIVIDENDS $CTM $APA $SMMT $WIMI 6
0 · Reply
ChillPill1972
ChillPill1972 Oct. 9 at 10:40 PM
$SMMT We should get another PR prior to ESMO next weekend!
0 · Reply
Omegacy2
Omegacy2 Oct. 9 at 9:19 PM
$SMMT was 23.5 now 22 i called it 20-19. $NBIS was 135 now 132.4s hod 133.3s. i called it 86-87. i got it right again. in few weeks. @EnvyMyPortfolio
0 · Reply
Magic8BallResponse
Magic8BallResponse Oct. 9 at 7:34 PM
$SMMT
0 · Reply
ArbiterOfFarts
ArbiterOfFarts Oct. 9 at 7:30 PM
$IOVA I Don't follow IOVA, but when IOVA people come over to $SMMT to shit on it they always talk about how IOVA has a product that is out and it works well. I'm not here to say it doesn't work well because I've done zero research, my legitimate question is, if what you have works and works well why has this not broken out yet?
4 · Reply
Teluride
Teluride Oct. 9 at 5:59 PM
$SMMT Some lost their compass today. The tribe still knows the stars and they’re pointing north.
1 · Reply
TruthBroker2
TruthBroker2 Oct. 9 at 1:18 PM
$SMMT $PLSE
0 · Reply
SmokeWagon
SmokeWagon Oct. 9 at 1:11 PM
$SMMT
0 · Reply
TruthBroker2
TruthBroker2 Oct. 9 at 11:41 AM
$SMMT
0 · Reply
BOXLinvestor
BOXLinvestor Oct. 9 at 11:24 AM
$SMMT Summit Therapeutics (option volume 10-08-25) 23.34 +4.7% | 1,019 trades | total $1.05 M | 90-day avg $1.75 M × 0.60 call $882.3 K | put $163.1 K | 91% single-leg, 9% multi-leg
0 · Reply
BOXLinvestor
BOXLinvestor Oct. 9 at 7:39 AM
$SMMT Summit Therapeutics (option volume 10-08-25) 23.34 +4.7% | 1,019 trades | total $1.05 M | 90-day avg $1.75 M × 0.60 call $882.3 K | put $163.1 K | 91% single-leg, 9% multi-leg
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 9 at 6:37 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $SMMT Current Share Price: $23.34 Contracts: $SMMT January 15, 2027 $25 Calls Scale in: $7.70- $9.42 Scale out: $11.98-$15.41 Can Easily Capture: 60% ROI Blended DTE: 463 Days | Join Elites here: https://liquidtheta.com/
0 · Reply
CoyoteUgly
CoyoteUgly Oct. 8 at 11:58 PM
$SMMT
0 · Reply
Letsdothis
Letsdothis Oct. 8 at 10:11 PM
$SMMT 😘
0 · Reply
Teluride
Teluride Oct. 8 at 5:53 PM
$SMMT
0 · Reply
BigBeardTrader
BigBeardTrader Oct. 8 at 4:17 PM
$SMMT
0 · Reply
SmokeWagon
SmokeWagon Oct. 8 at 3:49 PM
$SMMT
0 · Reply